ALKS vs. MDGL, FOLD, IONS, GERN, AGIO, DVAX, LGND, PCRX, IRWD, and MNKD
Should you be buying Alkermes stock or one of its competitors? The main competitors of Alkermes include Madrigal Pharmaceuticals (MDGL), Amicus Therapeutics (FOLD), Ionis Pharmaceuticals (IONS), Geron (GERN), Agios Pharmaceuticals (AGIO), Dynavax Technologies (DVAX), Ligand Pharmaceuticals (LGND), Pacira BioSciences (PCRX), Ironwood Pharmaceuticals (IRWD), and MannKind (MNKD). These companies are all part of the "pharmaceutical preparations" industry.
Alkermes (NASDAQ:ALKS) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both mid-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations.
Alkermes has a net margin of 21.39% compared to Madrigal Pharmaceuticals' net margin of 0.00%. Alkermes' return on equity of 16.10% beat Madrigal Pharmaceuticals' return on equity.
Alkermes received 238 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. Likewise, 70.84% of users gave Alkermes an outperform vote while only 68.56% of users gave Madrigal Pharmaceuticals an outperform vote.
95.2% of Alkermes shares are held by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 4.8% of Alkermes shares are held by company insiders. Comparatively, 23.9% of Madrigal Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Alkermes has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.
In the previous week, Alkermes had 6 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 14 mentions for Alkermes and 8 mentions for Madrigal Pharmaceuticals. Alkermes' average media sentiment score of 1.10 beat Madrigal Pharmaceuticals' score of 0.12 indicating that Alkermes is being referred to more favorably in the media.
Alkermes currently has a consensus price target of $35.38, indicating a potential upside of 48.63%. Madrigal Pharmaceuticals has a consensus price target of $356.73, indicating a potential upside of 74.44%. Given Madrigal Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Madrigal Pharmaceuticals is more favorable than Alkermes.
Alkermes has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500.
Summary
Alkermes beats Madrigal Pharmaceuticals on 12 of the 17 factors compared between the two stocks.
Get Alkermes News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALKS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALKS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alkermes Competitors List
Related Companies and Tools
